Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment

Author(s): Mizue Terai, Takami Sato.

Journal Name: Clinical Cancer Drugs

Volume 2 , Issue 1 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Clinical application of immune checkpoint blockades has dramatically changed the landscape of cancer immunotherapy, especially in the field of metastatic melanoma. For the first time in the history of treatment of melanoma, immunotherapies using immune checkpoint blockades such as anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and Program Death-1 (PD-1) antibodies have consistently shown regression of metastatic tumors with survival benefit. However, the treatment of metastatic melanoma with immune checkpoint blockades has also brought new scientific and clinical challenges to treating physicians and clinical investigators. Such new challenges include: (1) how should we manage/ minimize serious immune-related adverse events without sacrificing anti-cancer effects?, (2) how should we choose one immune checkpoint blockade over others and in what sequence?, (3) how should we combine the immune checkpoint blockade with other cancer treatments such as chemotherapy, radiotherapy and signal blockades?, and (4) how can we predict clinical response with new immunological agents? In this review, we provide an overview of the molecular basis of new immunotherapies for metastatic melanoma and discussed potential strategies to improve the treatment outcomes using immune checkpoint blockades alone or in combination with various therapeutic modalities.

Keywords: Melanoma, immunotherapy, CTLA-4, PD-1, PD-L1.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [4 - 15]
Pages: 12
DOI: 10.2174/2212697X02666150203212041

Article Metrics

PDF: 21